This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Yuan Y, Oster G.Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology 47: 535-541, No. 4, Apr 2008
Rights and permissions
About this article
Cite this article
Abatacept good value for money in methotrexate-refractory RA. Pharmacoecon. Outcomes News 554, 7 (2008). https://doi.org/10.2165/00151234-200805540-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805540-00017